In addition to their direct involvement in the cGAS‐STING‐IFN‐I signaling pathway, IFN α/β can mediate a variety of antitumor immune responses to overcome immunotherapy resistance, thereby enhancing the effectiveness of PD‐1/PD‐L1 blockade, as illustrated in Figure 7: (1) Enhancements in tumor immunogenicity: IFN‐α and IFN‐β potently stimulate the surface expression of MHC and tumor antigens on malignant cells, and they become recognizable by the immune system [154, 255]. Here, PDCD1 is linked to neoplasm.